covid
Buscar en
Progresos de Obstetricia y Ginecología
Toda la web
Inicio Progresos de Obstetricia y Ginecología Significado pronóstico de la densidad microvascular en el cáncer de ovario: es...
Journal Information
Vol. 47. Issue 1.
Pages 20-26 (January 2004)
Share
Share
Download PDF
More article options
Vol. 47. Issue 1.
Pages 20-26 (January 2004)
Full text access
Significado pronóstico de la densidad microvascular en el cáncer de ovario: estudio de una serie de 74 casos
Prognostic value of microvascular density in ovarian cancer in a series of 74 patients
Visits
4228
A. Moreno-Elolaa,*, J.A. Vidarta, L. Gonzálezb, M. Calvoa, J.A. Asenjob, V. Furiob, P. Coronadoa, R. Navazoa, M. Escuderoa
a Departamento de Obstetricia y Ginecología. Hospital Clínico San Carlos. Madrid
b Departamento de Anatomía Patológica. Hospital Clínico San Carlos. Madrid. España
This item has received
Article information
Resumen
Introducción

La cuantificación de la angiogénesis, en teoría, podría ser un factor determinante del pronóstico de ciertos carcinomas, ya que determina la posibilidad de metastatizar por parte del tumor primario.

Material y métodos

Se plantea un estudio retrospectivo sobre 74 pacientes con carcinoma de ovario en estadios I-IV (FIGO) y tratados en el Hospital Clínico San Carlos (Madrid) en el período 1985–1995. Se midió el índice angiogénico (determinación con anticuerpo monoclonal CD34, y cuantificación mediante un sistema digital de análisis de imagen Leika Q500IW con software propio), y se comparó el comportamiento de tumores con angiogénesis positiva y negativa en relación con los eventos de muerte y recidiva (estudio de regresión logística). El seguimiento mediano fue de 40,5 meses (rango, 3–105).

Resultados

La angiogénesis es un parámetro cuantificable, y es un factor pronóstico independiente para el riesgo relativo de muerte y recidiva para todos los estadios de carcinoma de ovario.

Palabras clave:
Angiogénesis
Carcinoma de ovario
Pronóstico
Abstract
Introduction

Angiogenesis is a determining factor in primary tumor metastasis and its quantification could have prognostic value in several carcinomas.

Material and methods

A retrospective study of 74 patients with ovarian carcinoma FIGO stage I-IV treated at the San Carlos Hospital from 1985-1995 was performed. Angiogenic index was determined by CD34 monoclonal antibody immunostaining, and quantification was achieved using a digital system (Leika Q500W). Univariate and multivariate analyses were performed to determine the relative risks of death and relapse. The median follow-up was 40.5 months (range, 3–105).

Results

Angiogenesis is a quantifiable parameter and an independent prognostic factor for relative risk of death and recurrence in all stages of ovarian carcinoma.

Keywords:
Angiogenesis
Ovarian carcinoma
Prognosis
Full text is only aviable in PDF
Referencias bibliográficas
[1.]
O. Albulafia, D.M. Sherer.
Angiogenesis of the ovary.
Am J Obstet Gynecol, 186 (2000), pp. 240-246
[2.]
J.D. Gordon, S. Mesiano, C.J. Zaloudek, R.B. Jaffe.
Vascular endothelial growth factor localization in human ovary and Fallopian tubes: possible role in reproductive function and ovary cysts formation.
J Clin Endocrinol Metab, 81 (1996), pp. 353-359
[3.]
J. Folkman.
Tumor angiogenesis: therapeutic implications.
N Engl J Med, 285 (1971), pp. 1182-1186
[4.]
J. Folkman.
What is the evidence that tumors are angiogenesis dependent?.
J Natl Cancer Inst, 82 (1990), pp. 4-6
[5.]
J. Folkman, P.A. D?Amore.
Blood vessel formation.
What is its molecular basis? Cell, 87 (1996), pp. 1153-1155
[6.]
D. Hanahan, J. Folkan.
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell, 86 (1996), pp. 353-364
[7.]
O. Abulafia, W.E. Triest, D.M. Sherer.
Angiogenesis in malignancies of the female genital tract.
Gynecologic Oncology, 72 (1999), pp. 220-231
[8.]
N. Weidner, J.P. Semple, J.R. Welch, J. Folkman.
Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma.
N Engl J Med, 324 (1991), pp. 1-8
[9.]
D. Feng, A. Nagy, J. Hipp, H.F. Dvorak, A.M. Dvorak.
Vesiculovacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine and serotonin.
J Exp Med, 183 (1996), pp. 1981-1986
[10.]
B.R. Zetter.
Angiogenesis and tumor metastasis.
Annu Rev Med, 49 (1998), pp. 407-424
[11.]
I.J. Fidler, L.M. Ellis.
The implications of angiogenesis for the biology and therapy of cancer metastasis.
Cell, 79 (1994), pp. 185-188
[12.]
N. Weidner, J. Folkman.
Tumor vascularity as a prognostic factor in cancer.
Important advances in oncology, pp. 167-190
[13.]
J.I. Fidler, R. Kumar, D.R. Bielemberg, L.M. Ellis.
Molecular determinants of angiogenesis in cancer metastasis.
Cancer J Sci Am, 4 (1998), pp. S58-S66
[14.]
A. Kraft, K. Weindel, A. Ochs, C. Marth, J. Zmija, P. Schumacher, et al.
Vascular endotelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Cancer, 85 (1999), pp. 178-187
[15.]
D. Hazelton, R.F. Nicosia, S. Nicosia.
Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
Clin Cancer Res, 5 (1999), pp. 823-829
[16.]
H.C. Hollingsworth, E.C. Kohn, S.M. Steinberg, M.L. Rothenberg, M.J. Merino.
Tumor angiogenesis in advanced ovarian carcinoma.
Am J Pathol, 147 (1995), pp. 3-41
[17.]
G. Gasparini, E. Bonoldi, G. Vitale, P. Verdeiro, P. Borachi, G.A. Pannizonni, et al.
Prognostic and predictive value of tumor angiogenesis in ovarian carcinomas.
[18.]
O. Albulafia, W.E. Triest, D.M. Sherer.
Angiogenesis in primary and metastatic epithelial ovarian carcinoma.
Am J Obstet Gynecol, 177 (1997), pp. 541-547
[19.]
W.M. Schoell, D. Pieber, O. Reich, M. Laoussen, M. Janicek, F. Guecer, et al.
Tumor angiogenesis as a prognostic factor in ovarian cancer.
Cancer, 80 (1997), pp. 2257-2262
[20.]
A. Obermair, R. Wasicky, A. Kaider, O. Preyer, A. Losch, S. Leodolter, et al.
Prognostic significance of tumor angiogenesis in epithelial ovarian cancer.
Cancer Lett, 138 (1999), pp. 175-182
[21.]
Y.S. Schiffenbauer, R. Abramovitch, G. Meir, N. Nevo, M. Holzinger, A. Itin, et al.
Loss of ovarian function promotes angiogenesis in human ovarian carcinoma.
Proc Natl Acad Sci USA, 94 (1997), pp. 13203-13218
[22.]
P.J. Paley, B.A. Goff, A.M. Gown, B.E. Greer, E.H. Sage.
Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer.
Gynecol Oncol, 78 (2000), pp. 336-341
[23.]
J. Fujimoto, H. Sakaguchi, R. Hirose, S. Ichigo, T. Tamaya.
Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma.
Cancer, 83 (1998), pp. 2528-2533
[24.]
S. Heimburg, M.K. Oehler, P. Kristen, T. Papadopoulos, H. Caffier.
The endothelial marker CD 34 in the assessment of tumour vascularisation in ovarian cancer.
Anticancer Res, 17 (1997), pp. 3149-3151
[25.]
M.E. Gordinier, H.Z. Zhang, R. Patenia, L.B. Levy, E.N. Atkinson, M.A. Nash, et al.
Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian carcinoma.
Clin Cancer Res, 5 (1999), pp. 2498-2505
[26.]
P.J. Paley, K.A. Staskus, K. Gebhard, D. Mohanraj, L.B. Twiggs, L. Carson.
Vascular endothelial growth factor expression in early stage ovarian carcinoma.
Cancer, 80 (1997), pp. 98-106
[27.]
S. Kodama, K. Tanaka, A. Tokunaga, N. Sudo, T. Takahashi, K. Matsui.
Multivariate analysis of prognostic factors in patients with ovarian cancer stage I and II.
Int J Gynaecol Obstet, 56 (1997), pp. 147-153
[28.]
P.S. Craft, A.L. Harris.
Clinical prognostic significance of tumour angiogenesis.
Ann Oncol, 5 (1994), pp. 305-311
[29.]
K. Dhinigra, G.N. Hortobagii.
Critical evaluation of prognostic factors.
Sem Oncol, 23 (1996), pp. 436-445
[30.]
M.S. O?Reilly, T. Boehm, Y. Shing, N. Fukai, G. Vasios, W.S. Lane, et al.
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.
Cell, 88 (1997), pp. 277-285
[31.]
E. Kohn.
Angiogenesis in ovarian carcinoma: a formidable biomarker.
Cancer, 80 (1997), pp. 2197-2221

Este trabajo ha sido financiado por una beca de la Comunidad Autónoma de Madrid (Dirección General de Investigación, Consejería de Sanidad) Cod. UNESCO 08.1/0011.1/1998

Copyright © 2004. Sociedad Española de Ginecología y Obstetricia
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos